Press release
Frontotemporal Dementia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio
Frontotemporal Dementia Pipeline Analysis
Frontotemporal Dementia Pipeline constitutes 15+ key companies continuously working towards developing 20+ Frontotemporal Dementia treatment therapies, analyzes DelveInsight.
Frontotemporal Dementia Overview:
Frontotemporal dementia (FTD) is a group of neurodegenerative disorders that affect the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language. Common symptoms include inappropriate social behavior, impulsivity, apathy, and language difficulties, with some forms also presenting motor issues similar to ALS or Parkinson's disease.
The main subtypes of FTD include behavioral variant FTD (bvFTD), characterized by severe personality and behavioral changes, and primary progressive aphasia (PPA), which impacts language and includes semantic and nonfluent variants. A more severe form, FTD with motor neuron disease (FTD-MND), combines cognitive decline with muscle weakness and atrophy.
FTD is linked to abnormal protein build-up (e.g., tau and TDP-43) and often has a genetic component, with nearly 40% of cases involving a family history. Diagnosis is challenging due to symptom overlap with other conditions and typically involves clinical evaluations, brain imaging, and sometimes genetic testing.
While no cure exists, treatment focuses on managing symptoms and enhancing quality of life. Medications can help control behavior, and therapies support communication and daily functioning. Additional support services are vital for patients and caregivers. FTD generally progresses over 6 to 8 years, making early diagnosis and comprehensive care essential for better outcomes.
Request for a detailed insights report on Frontotemporal Dementia pipeline insights [https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Frontotemporal Dementia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Frontotemporal Dementia Therapeutics Market.
Key Takeaways from the Frontotemporal Dementia Pipeline Report
*
DelveInsight's Frontotemporal Dementia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
*
Alector Inc., in collaboration with GSK, is developing Latozinemab (AL001) to treat Frontotemporal Dementia (FTD) caused by a progranulin gene mutation (FTD-GRN), with an anticipated US launch by 2025. This innovative therapy has the potential to significantly impact the FTD treatment landscape.
*
In October 2025, AviadoBio Ltd. and Astellas Pharma Inc. entered an exclusive option and license agreement for AVB-101, a Phase I/II gene therapy targeting FTD caused by progranulin mutations. This rare early-onset dementia leads to rapid cognitive decline and is often underdiagnosed in individuals under 65.
*
In October 2025, AC Immune, a Swiss biopharmaceutical company, announced that Life Molecular Imaging (LMI), its German partner, received FDA Fast Track Designation for the Tau PET tracer [18F]PI-2620. This imaging agent binds to a specific form of tau protein linked to Alzheimer's disease and FTD, enabling researchers to visualize its distribution and measure metabolic changes through PET imaging.
*
In February 2025, Alector announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Latozinemab. This investigational human monoclonal antibody aims to block sortilin, thereby increasing progranulin (PGRN) levels to treat FTD-GRN effectively.
*
Key Frontotemporal Dementia companies such as Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA, and others are evaluating new drugs for Frontotemporal Dementia to improve the treatment landscape.
*
Promising Frontotemporal Dementia pipeline therapies in various stages of development include AL001, TPN-101, AVB-101, VES001, and others.
Frontotemporal Dementia Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Frontotemporal Dementia Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Frontotemporal Dementia market.
Download our free sample page report on Frontotemporal Dementia pipeline insights @ https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Frontotemporal Dementia Emerging Drugs
*
AL001: Alector
*
TPN-101: Transposon Therapeutics
*
VES001: Vesper Bio
*
AVB-101: AviadoBio
Frontotemporal Dementia Companies
Approximately 15 or more key companies are actively developing therapies for Frontotemporal Dementia (FTD). Among these, Alector and others have drug candidates in the most advanced stage of development, specifically Phase III.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Frontotemporal Dementia Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Frontotemporal Dementia Therapies and Key Companies: Frontotemporal Dementia Clinical Trials and advancements [https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Frontotemporal Dementia Pipeline Therapeutic Assessment
- Frontotemporal Dementia Assessment by Product Type
- Frontotemporal Dementia By Stage
- Frontotemporal Dementia Assessment by Route of Administration
- Frontotemporal Dementia Assessment by Molecule Type
Download Frontotemporal Dementia Sample report to know in detail about the Frontotemporal Dementia treatment market @ Frontotemporal Dementia Therapeutic Assessment [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Frontotemporal Dementia Current Treatment Patterns
4. Frontotemporal Dementia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Frontotemporal Dementia Late-Stage Products (Phase-III)
7. Frontotemporal Dementia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Frontotemporal Dementia Discontinued Products
13. Frontotemporal Dementia Product Profiles
14. Frontotemporal Dementia Key Companies
15. Frontotemporal Dementia Key Products
16. Dormant and Discontinued Products
17. Frontotemporal Dementia Unmet Needs
18. Frontotemporal Dementia Future Perspectives
19. Frontotemporal Dementia Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Frontotemporal Dementia Pipeline Reports Offerings [https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=frontotemporal-dementia-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-transposon-therapeutics-alector-vesper-bio-aviadobio-passage-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frontotemporal Dementia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio here
News-ID: 4080530 • Views: …
More Releases from ABNewswire
Leading Provider of Accounting Services in Chicago, IL Sees Surge in Demand as N …
Chicago, IL - As entrepreneurship continues to flourish across the United States, Jeff Badu, a licensed Certified Public Accountant and wealth multiplier, reports a significant increase in demand from new business owners seeking expert financial guidance. The surge reflects a growing recognition among entrepreneurs that professional financial management is crucial for long-term business success and growth.
When establishing a new business, one of the most critical decisions entrepreneurs make is selecting…
Top Real Estate Listing Agent in Pleasant View, UT, Expands Services to Help Hom …
PLEASANT VIEW, UT - Responding to evolving real estate trends, Richard Curtis announces expanded services designed to help homeowners successfully navigate today's dynamic housing market. With innovative solutions tailored to current conditions, Curtis continues the client-centered approach that has defined his practice since 2002.
Curtis, recognized by many as one of the top Realtors in Pleasant View, UT [https://www.abnewswire.com/pressreleases/top-real-estate-agent-in-pleasant-view-ut-celebrates-over-two-decades-of-clientfocused-excellence_744146.html], brings more than two decades of experience to clients facing today's unique…
Top Fitness Coach in Portland, OR Expands Services to Austin Market Following Su …
Portland, OR - EVOLVE Integrative Personal Training is taking a significant step forward by expanding its services to Austin, Texas. This strategic growth comes as the company celebrates ten years of successful operations since its establishment in 2015, offering high-quality personal training services to individuals, couples, and small groups.
The expansion reflects the growing demand for EVOLVE's fitness coaching in Portland, OR [https://www.abnewswire.com/pressreleases/inhome-fitness-trainer-in-portland-or-celebrates-decade-of-success-with-feature-in-national-redfin-blog_747702.html], who focus on personalized fitness programs tailored to…
Top Real Estate Agent in Cedar City, UT, Reports 719% Surge in Luxury Home Sales …
Cedar City, UT - A remarkable transformation has occurred in the Cedar City housing market, with local data revealing a 719% increase in homes selling above $500,000 between 2019 and 2024. This dramatic shift highlights the changing landscape of real estate in this four-season community.
Matt Bagley, a top real estate listing agent in Cedar City, UT [https://www.abnewswire.com/pressreleases/top-realtor-in-cedar-city-ut-marks-20-years-in-business_747948.html] who began his business career in 2005, has witnessed this evolution firsthand. "In…
More Releases for Frontotemporal
Frontotemporal Disorder Treatment Market Size, Share, Impressive Industry Growth …
The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number…
Improvement In Cognitive Empathy to Drive The Frontotemporal Dementia Treatment …
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
Steadfast Growth Of The Frontotemporal Dementia Treatment Market On The Anvil
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
Global Frontotemporal Disorder Treatment Market Size, Competitive Analysis, Shar …
Orion Market Research
Global Frontotemporal Disorder Treatment Market Size, Competitive Analysis, Share, Forecast- 2020-2026
Request a Free Sample @ https://www.omrglobal.com/request-sample/frontotemporal-disorder-treatment-market
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
The global frontotemporal disorder treatment market is projected to grow at a considerable CAGR of around 5% during the forecast period (2020-2026). The increasing prevalence of frontotemporal disorder along with the growing geriatric population which is more susceptible…
Frontotemporal Disorders Treatment Market to Grow at a CAGR of US$ 451.4 Mn, By …
According to the latest research by the company, the global frontotemporal disorders treatment market is expected to be valued at US$ 451.4 Mn, by 2028 end. The report on the frontotemporal disorders treatment market projects major growth potential with average year-on-year growth rate of 4.7% through 2028.
The increasing funding by the governments across the globe for R&D is projected to be the major factor expected to propel the growth of…
Frontotemporal Disorders Treatment Market Dynamics and Key Players 2017 – 2027
Frontotemporal disorders, most commonly known as Pick’s disease, are damage to the nerve cells in specific area of brain that is frontal and temporal lobes. Frontotemporal disorders lead to dementia which alter the identity, conduct, dialect and development of muscles. Due to frontotemporal disorders, numerous conceivable indications may result, including strange practices, emotional issues, difficulty in working, or trouble with strolling. Frontotemporal degenerations are mainly caused due to group of…
